

RESEARCH

Open Access

Serum Matrix Metalloproteinase-7 is an independent prognostic biomarker in advanced bladder cancer

Mounira El Demery¹, Gaiané Demirdjian-Sarkissian², Simon Thezenas³, William Jacot⁴, Yassine Laghzali³, Bruno Darbouret², Stéphane Culine⁵, Xavier Rebillard⁶ and Pierre-Jean Lamy^{7*}

Abstract

Background: Urine markers have been studied extensively but there is a lack of blood prognostic markers in bladder cancer. MMP-7 is produced by stromal cells and by tumor cells and is overexpressed in a variety of epithelial and mesenchymal tumors. In this study, we assessed with an immunoassay we developed, the prognostic value of serum MMP-7 in a series of patients with advanced bladder cancer.

Methods: Serum samples were collected from 56 patients with advanced bladder cancer who were treated at the Montpellier Cancer Institute between March 2003 and December 2004. MMP-7 was quantified in serum samples by using a homogeneous sandwich fluoroimmunoassay we developed based on the time resolved amplified cryptate emission (TRACE) technology.

Results: The median overall survival of the study population was 2.2 years (95% CI, 1.4 to 3.0) with 1- and 5-year survival rates of 73% (95% CI, 59% to 82%) and 25% (95% CI, 14% to 37%), respectively. High MMP-7 serum levels were associated with poor survival. Using a cut-off value of 11.5 ng/mL, the median overall survival was 3.0 years (95% CI, 1.5 to 5.1) for patients with MMP-7 serum level <11.5 ng/mL and 1.3 years (95% CI, 0.8 to 2.5) for patients with serum level ≥11.5 ng/mL. Multivariate analysis identified high MMP-7 serum concentration as an independent prognostic factor for survival in patients with advanced bladder cancer (R = 2.1, 95% CI, 1.1 to 4.4).

Conclusions: Our results show that the MMP-7 serum concentration is an independent prognostic factor in patients with locally advanced and or metastatic bladder cancer.

Keywords: MMP-7; Bladder cancer; Prognosis; Urothelial tumors; Serum; Biomarker; Tumor markers; Overall survival

Background

Bladder urothelial cell carcinoma (BUCC) is the fourth most common cancer in men and overall the fifth most common cancer with 11965 new cases and 4772 BUCC-related deaths in France in 2012 [1]. At diagnosis, approximately 75% of bladder cancers are non-muscle invasive [pTa, pT1, carcinoma in situ (CIS)], 25% are muscle-invasive (pT2-pT4) and 5% are metastatic (N1-3 or M1) [2]. The standard treatment includes transurethral resection of the bladder tumor (TURBT) and intravesical chemotherapy or immunotherapy for superficial

tumors and radical cystectomy for non muscle invasive tumors. However, 50-70% of patients will experience tumor recurrence within 5 years. The 5-year survival rate of patients with non-muscle invasive disease is between 95% (Ta tumors) and 75% (T1 tumors), and almost 25% of patients with a Ta-T1 tumor will eventually develop invasive disease [3]. The 5-year survival rate further decreases in patients with muscle invasive or metastatic disease (60% and 35% for T2 and T3 tumors, respectively, and only 10% for T4 tumors) [4]. The bladder cancer heterogeneity in terms of clinical behavior means that prognostic tools based on clinical and pathological variables are not accurate enough to reliably

* Correspondence: Pierre-Jean.Lamy@icm.unicancer.fr

⁷Department of Biology and Oncogenetics, Institut Régional du Cancer de Montpellier (ICM), Val d'Aurelle, cedex 05, 34298 Montpellier, France
Full list of author information is available at the end of the article

predict the tumor biological behavior or to guide treatment choices. Urine markers have been studied extensively but cannot be easily standardized due to diuresis variations, and blood prognostic markers for

Table 1 Patients' characteristics

	N°	%
Sex		
M	47	83.9
F	9	16.1
AGE	Median (Range)	69 (49 - 91)
Histology		
Urothelial	47	83.9
Other	3	5.4
Unknown	6	10.7
TNM at diagnosis		
T		
Tx	4	7.1
T2	2	3.6
T3	16	28.6
T4	34	60.7
N		
Nx	31	55.4
N0	12	21.4
N1	10	17.9
N2	3	5.4
M		
M0/Mx	46	82.1
M1	10	17.9
Grade		
Gr2	1	1.8
Gr3	46	82.1
Unknown	9	16.1
PS		
0	31	55.4
1	17	30.4
2	7	12.5
3	1	1.8
Treatment		
Surgery	18	32.1
Radio-chemotherapy	12	21.4
Chemotherapy	39	69.6
Radiotherapy	1	1.8
Palliative care	3	5.4
MMP7 (ng/mL)		
Mean (s.d.)	10.6 (8.8)	
Median (range)	8.5 (2.8-44.2)	

Table 2 Univariate cox regression analysis using MMP-7 categories (deciles)

MMP7 category (ng/mL)	HR (95% CI)	P
<3.6	1.0	-
[3.6 - 4.2]	0.4 (0.1-0.2)	0.296
[4.2 - 5.2]	2.9 (0.7-12.1)	0.126
[5.2 - 7.2]	1.5 (0.4-5.8)	0.493
[7.2 - 8.4]	4.8 (1.2-19.5)	0.026
[8.4 - 9.6]	1.2 (0.3-5.7)	0.789
[9.6 - 11.5]	0.7 (0.2-3.0)	0.682
[11.5 - 13.4]	5.4 (1.3-23.6)	0.022
[13.4 - 17.5]	3.4 (0.9-13.1)	0.072
≥ 17.5	3.7 (0.9-15.5)	0.067

The MMP7 \geq 11.5 ng/mL categories showed consecutive P<0.1 values.

bladder cancer are lacking. New markers to aid in the diagnosis and prognosis as well as to identify the optimal treatment and monitor tumor progression are therefore needed [5].

Matrix Metalloproteinases (MMPs) are a family of zinc-dependent proteolytic enzymes that cleave extracellular matrix proteins (ECMs). ECM degradation is an important step in both physiological (embryonic development, reproduction, wound healing) and pathological

Table 3 Univariate survival analyses

Variable	HR [95%CI]	P
Gender		
Male	1.0	
Female	0.75 [0.34 ; 0.63]	0.472
pN		
pN0	1.0	
pN+	2.33 [0.87 ; 6.24]	0.090
pM		
M0	1.0	
M1	1.64 [0.74 ; 3.62]	0.225
Grade		
2	1.0	
3	0.95 [0.13 ; 7.00]	0.96
Hemoglobin		
Normal	1.0	
Abnormal	1.39 [0.76 ; 2.56]	0.29
PS		
0-1	1.0	
2-4	1.31 [0.58 ; 2.98]	0.51
MMP-7		
<11.5 ng/mL	1.0	
≥11.5 ng/mL	2.55 [1.33 ; 4.90]	0.005

Table 4 Multivariate survival analysis

		HR (CI 95%)	P
Gender	Male	1.0	0.421
	Female	0.7 (0.3-1.6)	
OMS	0/1	1.0	0.788
	2/3/4	1.1 (0.5-2.8)	
MMP-7	<11.5 ng/mL	1.0	0.035
	≥11.5 ng/mL	2.1 (1.1- 4.4)	
Hemoglobin	Normal	1.0	0.337
	Abnormal	1.4 (0.7-2.6)	

processes (arthritis, tumor progression and metastasis formation) [6]. Furthermore, MMPs can influence several molecular processes involved in tumor progression through their ability to cleave pro-apoptotic factors, cell surface molecules, cell adhesion molecules and growth factors [7,8]. MMPs can mobilize pro-angiogenic inhibitors, such as endostatin and angiostatin [9,10]. MMP-7, also known as matrilysin, is the smallest MMPs; its molecular weight as a proenzyme is 28 KDa and it decreases to 19 KDa after activation induced by plasmin and trypsin [11]. MMP-7 is expressed in the ductal and glandular epithelia of normal mammary and parotid glands, liver, pancreas and prostate. In human tumors, MMP-7 is produced by stromal cells (macrophages, fibroblasts and endothelial cells) and also by tumor cells [6]. MMP-7 is overexpressed in a variety of epithelial and mesenchymal tumors, such as esophageal, colon, liver, renal and pancreatic cancer [12-14]. Furthermore, increased circulating levels of MMP-7 have been correlated with metastatic disease and poor patients' survival in colorectal, ovarian and renal cancer [15-18]. Elevated

MMP-7 concentration was detected in urine samples from patients with regional or distant metastasis in comparison to patients with localized disease and controls, suggesting that MMP-7 could be a putative biomarker for the diagnosis and monitoring of bladder cancer [19]. Moreover, MMP-7 plasma levels are significantly higher in patients with bladder cancer at high risk of disease progression [20]. Similarly, analysis of MMP-7 plasma level in 135 patients with localized bladder cancer (≥T1) confirmed the significant association of MMP-7 level with cancer-related death [21].

In the present study, we measured MMP-7 serum levels particularly in patients with advanced bladder cancer and analyzed their correlation with clinical parameters to determine whether serum MMP-7 could also be used as a prognostic marker.

Methods

Clinical samples

Serum samples from 56 patients with bladder cancer were collected in the Department of Medical Oncology at the Institut du Cancer de Montpellier (ICM) between March 2003 and December 2004 and stored in a certified AFNOR 96900 biobank (ICM biobank number: **BB-0033-00059**). The patients' medical records were used to extract information on the clinico-pathological features, last follow-up and cause of death. This study was performed in compliance with the relevant French ethical standards and was validated by our Institutional Research Ethics Board (CORT). According to our biobank policy all patients gave their general consent for the use of their biological samples in research.




Figure 1 Overall survival probability function according to serum MMP-7 level in bladder cancer.

Measurement of MMP-7 serum level

We previously developed and validated a homogeneous sandwich fluorimmunoassay [18] based on the TRACE technology. The specific MMP-7 immunoassay was set up using two monoclonal anti-human MMP-7 antibodies (29S and 01S) generated by immunization of female BALB/c mice with human MMP-7 recombinant protein (R&D Systems Europe Ltd., Abingdon, UK). The immunoassay was performed by incubating 50 μ L of each patient's serum sample or calibrator with 50 μ L of AF647-conjugated 29S-antibody solution) and 50 μ L of cryptate-conjugated 01S-antibody solution at 37°C in a BRAHMS KRYPTOR automate (Thermo Fisher Scientific, Hennigsdorf, Germany), according to the manufacturer's instructions and as previously described [18]. Results were given in μ g/L. Standards ranged from 0.5 to 40 μ g/L.

Statistical analysis

Categorical variables were reported using contingency tables. For continuous variables, median and range were computed. To investigate their associations with the clinical, pathological and biological parameters, univariate statistical analyses were performed using the Pearson's chi-square test or the Fisher's exact test, when applicable, for categorical variables, and using the Kruskal-Wallis test or the Student's t test for continuous variables. Survival times were measured from the date of the diagnosis of bladder cancer to the event date (or to the last available follow-up, if not applicable). Overall survival rates (with event defined as death from any cause) were estimated according to the Kaplan-Meier method and presented with 95% confidence intervals (CIs). Patients alive were censored at the date of the last follow-up. The median follow-up was estimated according to the « reverse Kaplan-Meier method » and presented with 95% CIs. Survival curves were drawn and the log-rank test was performed to assess differences between groups. Multivariate analyses were carried out using Cox proportional hazards regressions with a stepwise selection procedure to investigate known prognostic factors. Hazards Ratios (HR) with 95% CIs show the risk of experiencing the event (death from any cause) during the follow-up period. All reported P values are two-sided and the significance level was set at 5% ($p < 0.05$). Statistical analyses were performed using the STATA 11 software (*Stata Corporation, College Station, TX*).

Results

Clinical background

Patient's characteristics at time of diagnosis are shown in Table 1. A total of 56 patients who received a diagnosis of urothelial tumor between January 1995 and November 2004 were enrolled in this study. At the

time of the analysis, 35/56 patients (62.5%) had metastatic disease and 20 patients (35.7%) had localized disease. Seven patients (12.5%) had a Performance Status (PS) of 2/3. Forty-six (82.1%) had grade 3 tumor at diagnosis. Surgery was performed for 18 (32.1%) patients; radical cystectomy for 13 (23.2%) patients and nephrectomy for 5 (8.9%) patients. Seventeen patients (30.4%) received post-operative chemotherapy and 12 (21.4%) concomitant radio-chemotherapy. The median follow-up was 8.1 years (range: 0.2- 16.2 years).

MMP-7 serum concentration and survival:

The median overall survival of the study population was 2.2 years (95% CI 1.4- 3.0) with 1- and 5-year survival rates of 73% (95% CI 59-82%) and 25% (95% CI 14-37%), respectively. Among the 56 patients, 47 died (38 patients: cancer-related death; 9 patients: non-cancer related death). MMP-7 serum levels were categorized in deciles and then the effect of MMP-7 serum level on the survival time was assessed (univariate Cox regression analysis). MMP-7 serum levels higher than 11.5 ng/mL were significantly associated with poor prognosis (Table 2). Therefore, 11.5 ng/mL was used as cut-off to classify patients as low (<11.5 ng/mL serum MMP-7) and high risk (\geq 11.5 ng/mL serum MMP-7) for the univariate (Table 3) and multivariate analysis (Table 4). The median overall survival of patients with MMP-7 serum level <11.5 ng/mL and those with serum level \geq 11.5 ng/mL was 3.0 years (95% CI 1.5-5.1) and 1.3 years (95% CI 0.8-2.5), respectively (Figure 1); $p(\log \text{rank}) = 0.004$ (Table 1). Multivariate analysis indicated that MMP-7 serum level \geq 11.5 ng/mL was an independent predictor of poor survival (Table 4).

Discussion

The prognosis of advanced bladder cancer is generally poor [22]. Therefore, new therapeutic strategies are needed to improve the outcome of patients with locally advanced or metastatic cancer. In this setting, the knowledge of prognostic determinants might be important for treatment planning and for patients' inclusion in clinical trials.

MMP-7 is overexpressed in many cancers. Previous studies have reported elevated MMP-7 concentration in urine samples and also in plasma samples from patients with bladder cancer. In urine samples no significant difference was detected in MMP-7 levels between bladder cancer patients and controls, suggesting that only MMP-7 plasma levels could be a putative biomarker for the diagnosis of bladder cancer [19-21]. Moreover, MMP-7 plasma levels may be used to identify patients at high risk of diseases progression [20,21].

The aim of this study was to analyze the prognostic value of MMP-7 serum level particularly in advanced bladder

cancer by quantifying MMP-7 concentration (using a sandwich fluorimmunoassay) in serum samples from 56 patients with locally advanced or metastatic disease at time of MMP-7 analysis. Survival analysis made after categorization of MMP-7 serum levels into deciles indicated that concentrations higher than 11.5 ng/mL were associated with higher risk of poor prognosis ($P < 0.07$). Multivariate analyses carried out using this cut-off and Cox proportional hazards regressions with a stepwise selection procedure to investigate the association with known prognostic factors showed that MMP-7 serum level is a strong independent prognostic factor of overall survival (HR = 2.1, 95% CI 1.1-4.5, $p = 0.035$). Our findings are consistent with those reported by Szarvas et al who analyzed MMP-7 gene expression and serum level in 179 patients with urothelial bladder cancer (160 patients with BUCC and 19 controls). The study showed that MMP-7 was significantly higher in both tumor and serum samples from patients with metastatic BUCC than in those without known metastasis. Furthermore, both high tissue and serum levels were stage- and grade-independent risk factors for metastasis and cancer-related death [23].

Although, the power of our analysis was reduced due to the small number of patients, our results suggest that MMP-7 serum level may be a prognostic factor for patients with locally advanced and or metastatic bladder cancer. We defined a MMP-7 cut-off value (11.5 ng/mL) that clearly differentiates two groups of patients: the overall survival of patients with low MMP-7 serum level was 3 years versus only 1.3 year for patients with high MMP-7 serum level.

Conclusions

Our results show that the MMP-7 serum concentration is an independent prognostic factor in patients with locally advanced and or metastatic bladder cancer. Further studies are needed to determine how MMP-7 can adequately assign patients to prognostic subgroups for different treatments and how it can be used in the design of clinical trials.

Abbreviations

MMP-7: Matrix metalloproteinase-7; TRACE: Time resolved amplified cryptate emission; BUCC: Bladder urothelial cell carcinoma; TURBT: Transurethral resection of the bladder tumor; ECM: Extracellular matrix; HR: Hazards ratio; CI: Confidence interval; PS: Performance status.

Competing interests

GS and BD are employees of Cezanne SAS, (part of Thermo Fisher Scientific).

Authors' contributions

ME collected and assembled the data, and drafted the manuscript. GDS developed the immunoassay and carried out the assays. ST performed the statistical analysis and drafted the manuscript. WJ provided study patients and material, collected and interpreted the data and helped to draft the manuscript. YL performed the statistical analysis. BD participated in the conception of the immunoassay and design of the study and helped to draft the manuscript. SC participated in the conception and design of the study,

provided study material, interpreted the data and helped to draft the manuscript. XR provided study patients and material, interpreted the data and helped to draft the manuscript. PJJ participated in the conception and design of the study, interpreted the data and drafted the manuscript. All authors read and approved the final manuscript.

Acknowledgments

This study was supported by the Institut Régional du Cancer Montpellier - Val d'Aurelle and by Cézanne SAS (part of Thermo Fisher Scientific).

Author details

¹Department of Medical Oncology, Cap d'Or Clinic, La Seyne sur Mer, France.

²Clinical Diagnostic Division, Thermo Fisher Scientific, Nimes, France.

³Department of Biostatistics, Institut Régional du Cancer de Montpellier (ICM), Val d'Aurelle, Montpellier, France. ⁴Department of Medical Oncology, Institut Régional du Cancer de Montpellier (ICM), Val d'Aurelle, Montpellier, France. ⁵Hôpital Saint-Louis, APHP, Saint-Louis, France. ⁶Clinique Beausoleil, Montpellier, France. ⁷Department of Biology and Oncogenetics, Institut Régional du Cancer de Montpellier (ICM), Val d'Aurelle, cedex 05, 34298 Montpellier, France.

Received: 27 June 2014 Accepted: 3 September 2014

Published online: 28 October 2014

References

- Grosclaude P, Velten M, Daubisse-Marliac L: **Incidence of urogenital Tumors**. In Binder-Foucard F, Belot A, Delafosse P, et al. *Estimation nationale de l'incidence et de la mortalité par cancer en France entre 1980 et 2012. Tumeurs solides. Saint-Maurice (Fra): Institut de veille sanitaire*; 2013.
- Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J: **EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder**. *Eur Urol* 2008, **54**:303-314.
- Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffiuix C, Denis L, Newling DW, Kurth K: **Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials**. *Eur Urol* 2006, **49**:466-465. discussion 475-467.
- Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE, Vazina A, Gupta A, Bastian PJ, Sagalowsky AI, Schoenberg MP, Lerner SP: **Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium**. *J Urol* 2006, **176**:2414-2422. discussion 2422.
- Karakiewicz PI, Shariat SF, Palapattu GS, Gilad AE, Lotan Y, Rogers CG, Vazina A, Gupta A, Bastian PJ, Perrotte P, Sagalowsky AI, Schoenberg MP, Lerner SP: **Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder**. *J Urol* 2006, **176**:1354-1361. discussion 1361-1352.
- Szarvas T, Vom Dorp F, Ergun S, Rubben H: **Matrix metalloproteinases and their clinical relevance in urinary bladder cancer**. *Nat Rev Urol* 2011, **8**:241-254.
- Vargo-Gogola T, Crawford HC, Fingleton B, Matrisian LM: **Identification of novel matrix metalloproteinase-7 (matrilysin) cleavage sites in murine and human Fas ligand**. *Arch Biochem Biophys* 2002, **408**:155-161.
- Lee KH, Choi EY, Hyun MS, Jang BI, Kim TN, Kim SW, Song SK, Kim JH, Kim JR: **Association of extracellular cleavage of E-cadherin mediated by MMP-7 with HGF-induced in vitro invasion in human stomach cancer cells**. *Eur Surg Res* 2007, **39**:208-215.
- Ito TK, Ishii G, Saito S, Yano K, Hoshino A, Suzuki T, Ochiai A: **Degradation of soluble VEGF receptor-1 by MMP-7 allows VEGF access to endothelial cells**. *Blood* 2009, **113**:2363-2369.
- Cornelius LA, Nehring LC, Harding E, Bolanowski M, Welgus HG, Kobayashi DK, Pierce RA, Shapiro SD: **Matrix metalloproteinases generate angiotatin: effects on neovascularization**. *J Immunol* 1998, **161**:6845-6852.
- Shiomi T, Okada Y: **MT1-MMP and MMP-7 in invasion and metastasis of human cancers**. *Cancer Metastasis Rev* 2003, **22**:145-152.
- Jones LE, Humphreys MJ, Campbell F, Neoptolemos JP, Boyd MT: **Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival**. *Clin Cancer Res* 2004, **10**:2832-2845.
- Miyata Y, Iwata T, Ohba K, Kanda S, Nishikido M, Kanetake H: **Expression of matrix metalloproteinase-7 on cancer cells and tissue endothelial cells in**

- renal cell carcinoma: prognostic implications and clinical significance for invasion and metastasis. *Clin Cancer Res* 2006, **12**:6998–7003.
14. Yamamoto H, Iku S, Adachi Y, Imsumran A, Taniguchi H, Noshio K, Min Y, Horiuchi S, Yoshida M, Itoh F, Imai K: **Association of trypsin expression with tumour progression and matrilysin expression in human colorectal cancer.** *J Pathol* 2003, **199**:176–184.
 15. Maurel J, Nadal C, Garcia-Albeniz X, Gallego R, Carcereny E, Almendro V, Marmol M, Gallardo E, Maria Auge J, Longaron R, Martinez-Fernandez A, Molina R, Castells A, Gascon P: **Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients.** *Int J Cancer* 2007, **121**:1066–1071.
 16. Ramankulov A, Lein M, Johannsen M, Schrader M, Miller K, Jung K: **Plasma matrix metalloproteinase-7 as a metastatic marker and survival predictor in patients with renal cell carcinomas.** *Cancer Sci* 2008, **99**:1188–1194.
 17. Schummer M, Drescher C, Forrest R, Gough S, Thorpe J, Hellstrom I, Hellstrom KE, Urban N: **Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125.** *Gynecol Oncol* 2012, **125**:65–69.
 18. Sarkissian G, Fergelot P, Lamy PJ, Patard JJ, Culine S, Jouin P, Rioux-Leclercq N, Darboret B: **Identification of pro-MMP-7 as a serum marker for renal cell carcinoma by use of proteomic analysis.** *Clin Chem* 2008, **54**:574–581.
 19. Szarvas T, Singer BB, Becker M, Vom Dorp F, Jager T, Szendroi A, Riesz P, Romics I, Rubben H, Ergun S: **Urinary matrix metalloproteinase-7 level is associated with the presence of metastasis in bladder cancer.** *BJU Int* 2010, **107**:1069–1073.
 20. Szarvas T, Jager T, Becker M, Tschirdewahn S, Niedworok C, Kovalszky I, Rubben H, Ergun S, Vom Dorp F: **Validation of circulating MMP-7 level as an independent prognostic marker of poor survival in urinary bladder cancer.** *Pathol Oncol Res* 2011, **17**:325–332.
 21. Svatek RS, Shah JB, Xing J, Chang D, Lin J, McConkey DJ, Wu X, Dinney CP: **A multiplexed, particle-based flow cytometric assay identified plasma matrix metalloproteinase-7 to be associated with cancer-related death among patients with bladder cancer.** *Cancer* 2010, **116**:4513–4519.
 22. Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, Herr H, Higgins G, Boyle MG: **Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy.** *J Clin Oncol* 1999, **17**:3173–3181.
 23. Szarvas T, Becker M, Vom Dorp F, Gethmann C, Totsch M, Bankfalvi A, Schmid KW, Romics I, Rubben H, Ergun S: **Matrix metalloproteinase-7 as a marker of metastasis and predictor of poor survival in bladder cancer.** *Cancer Sci* 2010, **101**:1300–1308.

doi:10.1186/s40169-014-0031-4

Cite this article as: El Demery et al.: Serum Matrix Metalloproteinase-7 is an independent prognostic biomarker in advanced bladder cancer. *Clinical and Translational Medicine* 2014 **3**:31.

Submit your manuscript to a SpringerOpen[®] journal and benefit from:

- ▶ Convenient online submission
- ▶ Rigorous peer review
- ▶ Immediate publication on acceptance
- ▶ Open access: articles freely available online
- ▶ High visibility within the field
- ▶ Retaining the copyright to your article

Submit your next manuscript at ▶ springeropen.com
